Guidant gambles on CHF (Congestive Heart Failure) with $425 million Johnson & Johnson cardiac deal
This article was originally published in Clinica
Guidant and Johnson & Johnson have dramatically upped the stakes in the cardiac market through a complex series of deals. Guidant is to buy potentially breakthrough cardiac technology at the same time as freeing itself from litigation with J&J. In return, J&J will get up to $425 million from Guidant and access to rapid-exchange delivery technology.
You may also be interested in...
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.
Butterfly Network is disseminating the lessons from China and Italy about the poential value of lung ultrasound in the management of COVID-19 patients with respiratory disease.